Patent ID: 6841542
Filing Date: 2005-01-11
Classification: A61K,C12N

Abstract:
1. A method of decreasing the time for hematopoietic reconstitution of a patient following chemotherapy or radiation therapy, comprising: (a) obtaining a population of cells containing human stem cells from a subject; (b) enriching for the human stem cells in said population; (c) exposing the enriched stem cell population, ex vivo, to an oligomer antisense to TGF-β, under culture conditions and for a period of time effective to block the effect of TGF-β on replication and/or differentiation of said stem cells; (d) culturing the antisense oligomer treated stem cells to obtain cultured TGF-β blocking agent-treated stem cells, wherein the viability and differentiation state of said stem cells is maintained for at least 5 days; and (e) administering said cultured TGF-β blocking agent-treated stem cells to a subject, wherein the time required for in vivo reconstitution of at least one hematopoietic lineage is reduced relative to that of a subject who received stem cells not treated with an oligomer antisense to TGF-β.